Pancreatic Cancer Trial, Recruiting NCT05037461 Sponsor: J.M. de Laat Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT05037461
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have a pancreatic neuroendocrine tumour (a type of slow-growing pancreatic tumour) measuring between 2 cm and 3 cm in size.
  • People who have a tumour between 1.0 cm and 2.0 cm that has been growing at a moderate rate (2–4 mm per year) based on a series of follow-up scans.
  • People who have a tumour between 1.0 cm and 2.0 cm that has been growing very slowly (about 1 mm per year), confirmed across 3 or more follow-up scans over time.
  • People who have a remaining tumour between 1.0 cm and 2.0 cm that was left in place after a previous operation to remove a larger tumour.
  • People whose tumour has been reviewed by a specialist medical team and assessed as needing surgery.

Who may not be able to join:

  • People whose tumour is larger than 3 cm in size.
  • People whose tumour has been growing rapidly — more than 4 mm per year.
  • People whose tumour is causing symptoms by producing hormones (with an exception for a specific type called a gastrinoma located in the wall of the small bowel — confirm with trial site).
  • People currently being treated with a type of medication called a somatostatin analog.
  • People currently receiving chemotherapy.
  • People who have had a specific type of radiation treatment called peptide receptor radionuclide therapy within the past 12 months.
  • People who have previously had radiotherapy to the upper abdomen area.
  • People for whom an MRI scan is not suitable — for example, due to claustrophobia or having certain metal or electronic implants in the body.
  • People who are pregnant.
  • People whose cancer has spread to other parts of the body.
  • People whose general health and physical functioning is significantly limited, as measured by a standard medical scoring system (WHO performance score 3–4 — confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +31302507397

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
J.M. de Laat
Registry
ClinicalTrials.gov
Start date
1 May 2022
Est. completion
1 December 2025

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Change in tumor size

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov